Key Clinical Message:
Managing adult-onset Still’s disease (AOSD) complicated by severe
hepatitis requires vigilant monitoring and adaptable therapeutic
strategies. Standard treatments like Tocilizumab and Rituximab can cause
adverse reactions or lose efficacy. The interplay of systemic
inflammation and liver involvement highlights the need for ongoing
research to find effective, safe treatment alternatives.